Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Fig. 2

RUNX3 pathway signature predicted IO/TKI therapeutic benefit in RCC. (A) Survival benefit of IO/TKI versus TKI monotherapy for PFS in subgroups defined by CD8 + T cell infiltration and RUNX3 pathway signature. HR and P values, Cox regression model. (B-C) PFS of IO/TKI or TKI monotherapy in subgroups of (B) high-RUNX3 pathway signature and (C) low-RUNX3 pathway signature. P values, Kaplan-Meier analysis, and log-rank test

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us